Skip to main content
Full access
New Research
Published Online: 1 August 2013

Diffusion Tensor Imaging White Matter Endophenotypes in Patients With Schizophrenia or Psychotic Bipolar Disorder and Their Relatives

Abstract

Objective

Both schizophrenia and bipolar disorder are hypothesized to involve disordered brain connectivity. Prior studies show low white matter integrity, measured with diffusion tensor imaging, for both disorders. The authors studied disease specificity and endophenotypic status of these abnormalities by examining patients and their unaffected relatives.

Method

The 513 participants included probands with schizophrenia, probands with psychotic bipolar disorder, their first-degree relatives, and healthy comparison subjects. Fractional anisotropy measures of white matter integrity were collected at two sites as a part of the Bipolar-Schizophrenia Network on Intermediate Phenotypes project. Relatives with cluster A or B personality characteristics were further examined.

Results

Both the probands with schizophrenia and those with psychotic bipolar disorder showed lower fractional anisotropy than the comparison subjects in multiple white matter regions; differences were more marked in schizophrenia. No significant differences existed between proband groups, but in some brain regions scores on a measure of the dimensional continuum between schizophrenia and bipolar disorder, the Schizo-Bipolar Scale, showed correlations with fractional anisotropy. Many regions affected in schizophrenia probands showed similar but smaller effects in relatives, with a continuous fractional anisotropy decrease from healthy subjects to relatives to cluster A/B relatives to probands. The pattern for psychotic bipolar disorder was similar but involved fewer brain regions. Effects in bipolar relatives were limited to younger subjects. Fractional anisotropy decreased with age in all groups; this decrease was exaggerated in schizophrenia but not psychotic bipolar disorder.

Conclusions

Fractional anisotropy was highly heritable, supporting its value as a potential endophenotype.

Formats available

You can view the full content in the following formats:

Supplementary Material

Supplementary Material (886_ds001.pdf)

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 886 - 898
PubMed: 23771210

History

Received: 21 November 2012
Revision received: 18 January 2013
Accepted: 4 February 2013
Published online: 1 August 2013
Published in print: August 2013

Authors

Affiliations

Pawel Skudlarski, Ph.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
David J. Schretlen, Ph.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
Gunvant K. Thaker, M.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
Michael C. Stevens, Ph.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
Matcheri S. Keshavan, M.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
John A. Sweeney, Ph.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
Carol A. Tamminga, M.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
Brett A. Clementz, Ph.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
Kasey O’Neil, B.Sc.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.
Godfrey D. Pearlson, M.D.
From the Olin Neuropsychiatry Research Center, Hartford Hospital/Institute of Living, Hartford, Conn.; the Departments of Psychiatry and Neurobiology, Yale School of Medicine, New Haven, Conn.; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the Beth Israel and Deaconess Medical Center, Harvard Medical School, Boston; the Department of Psychiatry, University of Texas Southwestern, Dallas; and the Departments of Psychology and Neuroscience, Bioimaging Research Center, University of Georgia, Athens, Ga.

Notes

Address correspondence to Dr. Skudlarski ([email protected]).

Funding Information

Dr. Sweeney reports receiving study drugs from Janssen and Seaside and serving on advisory boards of Takeda, Bristol-Myers Squibb, Pfizer, Roche, and Eli Lilly. Dr. Keshavan reports receiving grants from GlaxoSmithKline and Sunovion. Dr. Pearlson reports serving on a Bristol-Myers Squibb advisory panel. Disclosures for Dr. Tamminga, as a Deputy Editor of the American Journal of Psychiatry, were published in the January issue. The other authors report no financial relationships with commercial interests.
Supplementary Material
Funded by NIMH grants R37 MH-43375 and R01 MH-074797 to Dr. Pearlson, von Humboldt Foundation funding and NIMH grant MH-077862 to Dr. Sweeney, NIMH grant MH-78113 to Dr. Keshavan, NIMH grant MH-077851 to Dr. Tamminga, and NIMH grant R01 MH-077945 to Dr. Thaker.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share